Deal-happy Sanofi to buy cancer-drug developer

In its second half-billion-dollar deal in a week, Sanofi-Aventis has agreed to buy the U.S. cancer drug specialist BiPar Sciences, aiming to build up its presence in biotech oncology meds. Report